# A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

> **NCT04014205** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 81 (estimated)

## Conditions studied

- Part 1：r/r B-cell Malignancies
- Part 2：B-cell Malignancies

## Interventions

- **DRUG:** Orelabrutinib (ICP-022)

## Key facts

- **NCT ID:** NCT04014205
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-18
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-01-30
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04014205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04014205, "A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04014205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*